Search research articles
Contact Us
Filters
Showing results (41-50 of 52) with videos related to
Page
of 6
Sort By:
American Journal of Respiratory and Critical Care Medicine
|
December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial
Susan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Research Square
|
April 8, 2025
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Linda Harrison, Gustavo E Velasquez, Russell R Kempker, et al.
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Trials
|
August 15, 2025
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 13, 2016
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 14, 2016
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
The New England Journal of Medicine
|
May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Susan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Page
of 6
Search research articles
Search
Showing results (41-50 of 52) with videos related to
Sort By:
Page
of 6
American Journal of Respiratory and Critical Care Medicine
|
December 10, 2014
Daily rifapentine for treatment of pulmonary tuberculosis. A randomized, dose-ranging trial
Susan E Dorman, Radojka M Savic, Stefan Goldberg, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 30, 2022
Rifapentine With and Without Moxifloxacin for Pulmonary Tuberculosis in People With Human Immunodeficiency Virus (S31/A5349)
April C Pettit, Patrick P J Phillips, Ekaterina Kurbatova, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
December 17, 2021
Efavirenz Pharmacokinetics and Human Immunodeficiency Virus Type 1 (HIV-1) Viral Suppression Among Patients Receiving Tuberculosis Treatment Containing Daily High-Dose Rifapentine
Anthony T Podany, Michelle Pham, Erin Sizemore, et al.
Research Square
|
April 8, 2025
ACTG A5409 (RAD-TB): Study Protocol for a Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis
Linda Harrison, Gustavo E Velasquez, Russell R Kempker, et al.
Nature Communications
|
May 13, 2025
Author Correction: Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Trials
|
August 15, 2025
ACTG A5409 (RAD-TB): Study protocol for a phase 2 randomized, adaptive, dose-ranging, open-label trial of novel regimens for the treatment of pulmonary tuberculosis
Linda J Harrison, Gustavo E Velásquez, Russell R Kempker, et al.
Nature Communications
|
October 31, 2024
Risk-stratified treatment for drug-susceptible pulmonary tuberculosis
Vincent K Chang, Marjorie Z Imperial, Patrick P J Phillips, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
August 13, 2016
Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America
|
September 14, 2016
Executive Summary: Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America Clinical Practice Guidelines: Treatment of Drug-Susceptible Tuberculosis
Payam Nahid, Susan E Dorman, Narges Alipanah, et al.
The New England Journal of Medicine
|
May 5, 2021
Four-Month Rifapentine Regimens with or without Moxifloxacin for Tuberculosis
Susan E Dorman, Payam Nahid, Ekaterina V Kurbatova, et al.
Page
of 6